Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease

ClinicalTrials.gov ID: NCT02956486

Public ClinicalTrials.gov record NCT02956486. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 1:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for the studies E2609-G000-301 (NCT02956486, MissionAD1) and E2609-G000-302 (NCT03036280, MissionAD2) will be pooled.

Study identification

NCT ID
NCT02956486
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Eisai Co., Ltd.
Industry
Enrollment
2,212 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
50 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 20, 2016 (Actual)
Primary completion
Jan 15, 2020 (Actual)
Completion
Jan 15, 2020 (Actual)
Last update posted
Feb 3, 2021

2016 – 2020

United States locations

U.S. sites
88
U.S. states
25
U.S. cities
71
Facility City State ZIP Site status
Facility #1 Chandler Arizona 85226 —
Facility #1 Colton California 92324 —
Facility #1 Costa Mesa California 92626 —
Facility #1 Fullerton California 92835 —
Facility #1 Imperial California 92251 —
Facility #1 Irvine California 92618 —
Facility #1 Lemon Grove California 91945 —
Facility #1 Oceanside California 92054 —
Facility #2 Oceanside California 92054 —
Facility #1 Oxnard California 93030 —
Facility #1 Panorama City California 91402 —
Facility #1 San Diego California 92123 —
Facility #1 Denver Colorado 80218 —
Facility #1 Atlantis Florida 33462 —
Facility #1 Aventura Florida 33187 —
Facility #2 Aventura Florida 33187 —
Facility #1 Boynton Beach Florida 33437 —
Facility #1 Coral Gables Florida 33134 —
Facility #2 Coral Gables Florida 33134 —
Facility #1 Delray Beach Florida 33445 —
Facility #1 Doral Florida 33122 —
Facility #1 Hialeah Florida 33016 —
Facility #2 Miami Florida 33122 —
Facility #11 Miami Florida 33125 —
Facility #9 Miami Florida 33125 —
Facility #10 Miami Florida 33126 —
Facility #4 Miami Florida 33133 —
Facility #1 Miami Florida 33137 —
Facility #6 Miami Florida 33144 —
Facility #3 Miami Florida 33155 —
Facility #7 Miami Florida 33174 —
Facility #8 Miami Florida 33176 —
Facility #2 Orlando Florida 32801 —
Facility #1 Orlando Florida 32806 —
Facility #3 Orlando Florida 32807 —
Facility #1 Palm Beach Gardens Florida 33410 —
Facility #1 Pompano Beach Florida 33064 —
Facility #1 Port Charlotte Florida 33952 —
Facility #1 Port Orange Florida 32127 —
Facility #1 Spring Hill Florida 34609 —
Facility #1 Tampa Florida 33613 —
Facility #2 Tampa Florida 33614 —
Facility #1 The Villages Florida 32162 —
Facility #1 Atlanta Georgia 30328 —
Facility #1 Columbus Georgia 31909 —
Facility #1 Decatur Georgia 30033 —
Facility #1 Suwanee Georgia 30024 —
Facility #1 Meridian Idaho 83642 —
Facility #1 Northbrook Illinois 60062 —
Facility #2 Wichita Kansas 67214 —
Facility #1 Boston Massachusetts 2115 —
Facility #1 Farmington Hills Michigan 48334 —
Facility #1 Chesterfield Missouri 63005 —
Facility #1 City of Saint Peters Missouri 63303 —
Facility #1 O'Fallon Missouri 63368 —
Facility #2 St Louis Missouri 63104 —
Facility #1 Mount Arlington New Jersey 7856 —
Facility #2 Springfield New Jersey 7081 —
Facility #1 West Long Branch New Jersey 7764 —
Facility #1 Amherst New York 14226 —
Facility #1 Brooklyn New York 11229 —
Facility #1 New York New York 10032 —
Facility #1 Canton Ohio 44718 —
Facility #1 Centerville Ohio 45459 —
Facility #1 Cleveland Ohio 44195 —
Facility #1 Dayton Ohio 45459 —
Facility #1 Lakewood Ohio 44107 —
Facility #1 Westerville Ohio 43081 —
Facility #1 Oklahoma City Oklahoma 73116 —
Facility #1 Portland Oregon 97210 —
Facility #1 Jenkintown Pennsylvania 19046 —
Facility #1 Media Pennsylvania 19063 —
Facility #1 Philadelphia Pennsylvania 19104 —
Facility #1 East Providence Rhode Island 02914 —
Facility #1 Providence Rhode Island 2906 —
Facility #1 Port Royal South Carolina 29935 —
Facility #1 Cordova Tennessee 38018 —
Facility #2 Nashville Tennessee 37203 —
Facility #1 Nashville Tennessee 37212 —
Facility #1 Austin Texas 78757 —
Facility #1 Dallas Texas 75231 —
Facility #1 Houston Texas 77084 —
Facility #1 San Antonio Texas 78229-3900 —
Facility #3 San Antonio Texas 78240 —
Facility #1 Salt Lake City Utah 84108 —
Facility #1 Bennington Vermont 5201 —
Facility #1 Hampton Virginia 23666 —
Facility #1 Madison Wisconsin 53705 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 170 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02956486, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 3, 2021 · Synced Oct 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02956486 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →